Myfanwy Graham
Dados Biográficos
| ID | 7385404 |
|---|---|
| NOME | Myfanwy Graham |
| PRENOMES | Myfanwy |
| SOBRENOME | Graham |
| ASSINATURA | GRAHAM M |
| AFILIAÇÕES | Monash Addiction Research Centre, Eastern Health Clinical School, Monash University Melbourne Australia |
| ORCID | 0000-0003-0618-7497 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 5 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 5 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2023 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
International Policy Approaches for Higher THC Cannabis Products
Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations
A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study
BACKGROUND: We know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances. METHODS: We examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Australia, and New Zealand. The survey included questions on lifetime, past year, and pas…
‘The wild west of medicine’
A provisional evaluation of Australia's medical cannabis program
In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported …
Sem obras proeminentes nesta página.
A provisional evaluation of Australia's medical cannabis program
In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported …
‘The wild west of medicine’
International Policy Approaches for Higher THC Cannabis Products
Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations
A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study
BACKGROUND: We know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances. METHODS: We examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Australia, and New Zealand. The survey included questions on lifetime, past year, and pas…
Cannabis and Cannabinoid Research (5 obras) · Cannabis (4 obras) · Psychedelics and Drug Studies (4 obras) · Forensic Toxicology and Drug Analysis (3 obras) · Effects of cannabis (2 obras) · Business (1 obras) · Computer Science (1 obras) · Drug (1 obras) · Government (linguistics (1 obras) · Grey literature (1 obras)